BiotechTube

ZW171

Phase 1Terminated
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mesothelin-expressing Advanced Cancers

Conditions

Mesothelin-expressing Advanced Cancers

Trial Timeline

Sep 30, 2024 → Oct 1, 2025

NCT ID
NCT06523803

About ZW171

ZW171 is a phase 1 stage product being developed by Zymeworks for Mesothelin-expressing Advanced Cancers. The current trial status is terminated. This product is registered under clinical trial identifier NCT06523803. Target conditions include Mesothelin-expressing Advanced Cancers.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06523803Phase 1Terminated

Competing Products

1 competing product in Mesothelin-expressing Advanced Cancers

See all competitors
ProductCompanyStageHype Score
CT-95Context TherapeuticsPhase 1
25

Other Products from Zymeworks

Futibatinib + Ivosidenib + Zanidatamab + Trastuzumab + Neratinib + Encorafenib + Binimetinib + Niraparib + Cisplatin + GemcitabinePhase 3
72
Zanidatamab + Letrozole + TamoxifenPhase 2
47
ZW25Phase 2
47
ZW191Phase 1
28
ZW251Phase 1
28